- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02316691
B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease (BetTeRTED)
Study Overview
Status
Conditions
Detailed Description
All enrolled subjects will receive Intravenous Glucocorticoid (IVGC) therapy, which is currently the standard of care for TED patients. Subjects will receive the IVGC therapy at a facility chosen by them and their physician. If their disease does not respond to IVGC therapy, they will receive rituximab and/or surgical decompression and/or radiation which is also currently standard of care at a facility chosen by them and their physician. Prior to initiation of treatment and during the course of treatment, study patients will get research labs done along with routine labs and fill out questionnaires regarding their disease symptoms.
We will obtain 30 mL or 2 tablespoons of blood from subjects at initial evaluation and approximately Wk4, Wk 12, Wk 26, Wk 38, and Wk 52 (this may vary depending on when the patient comes in for their follow up visits, but the schedule approximates what is typical for standard of care in these patients) for mechanistic studies.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15261
- University of Pittsburgh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Willing and able to give informed consent
- Age 18 to 75 years of age
- Diagnosis of Thyroid Eye Disease (TED) with a CAS of ≥ 3. (Thyroid status can be euthyroid, hyper or hypothyroid.)
- Willingness to practice birth control for at least 12 months post treatment.
- Normal organ function, except if abnormal due to tumor involvement.
- Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment.
- Subject has provided written informed consent.
- Documentation of CD20 + status (for B cell malignancies).
- ANC: > 1000/mm3
- Adequate bone marrow function as indicated by a total white blood cell count of > 4 x 109/, hemoglobin of > 7 g/dl or a platelet count >100,000/mm³
- Adequate renal function as indicated by creatinine of <2.5.
- Adequate liver function, as indicated by AST or ALT <2x Upper Limit of normal unless related to primary disease.
Exclusion Criteria:
Patients will be excluded from the study based on the following criteria:
- Brittle insulin dependent diabetes [The term "brittle" refers to cases of diabetes in which there is an instability that leads to a disruption of life and often recurrent and/ or prolonged hospitalization]
- Pregnant or nursing patients
- Significant medical comorbidities that would make the risk of high dose steroids intolerable such as severe CHF, CAD, arrhythmias, renal insufficiency, infection or immune deficiency, systemic autoimmune disease, severe glaucoma etc.
- Absolute neutrophil count < 1500/mm³.
- Contraindication to use of rituximab
- Positive PPD and/or Quantiferon Gold TB test without prior anti-tuberculous therapy; active TB
- HIV or hepatitis infection or declined consent for HIV or hepatitis testing
- Use of rituximab in the prior 24 months for any reason other than TED
- Unwillingness to practice birth control for at least 12 months post treatment
- Pregnancy (a negative serum pregnancy test should be performed for all women of childbearing potential within 7 days of treatment), or lactating.
- Inability to comply with study and/or follow-up procedures.
- History of HIV.
- Presence of active infection.
- Presence of CNS metastases.
- New York Heart Association Classification III or IV heart disease (See Appendix D).
- Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
- History of psychiatric disorder.
- At the Investigator's discretion, receipt of a live vaccine within 4 weeks prior to randomization.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Thyroid Eye Disease
Blood samples will be drawn from subjects diagnosed with Thyroid Eye Disease.
This study is observational.
No interventions will be given as part of this study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Remission of disease activity (decrease in CAS of ≥ 2) at 26 weeks after first rituximab/placebo infusion
Time Frame: 26 weeks
|
Remission of symptoms and disease activity by 26 weeks after the first dose of medication.
Subjects will be followed for one year to assess relapse
|
26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Remission of disease activity (decrease in CAS of ≥ 2) at 6 and 14 weeks after first rituximab/placebo infusion.
Time Frame: 6 weeks
|
Remission of symptoms by week 6 after treatment and again at week 14.
|
6 weeks
|
Maintenance of CAS (defined as no worsening of CAS or requirement of other interventions such as surgical decompression/orbital radiation by 26 weeks after first rituximab/placebo infusion .
Time Frame: 26 weeks
|
Maintaining an absence of symptoms and disease activity.
|
26 weeks
|
Improvement in disease activity, as measured by CAS as a continuous variable at 6, 14, 26, 38 and 52 weeks after first infusion of rituximab,
Time Frame: 1 year
|
Improvement in symptoms and disease activity
|
1 year
|
ll adverse effects related to RTX
Time Frame: 1 year
|
Tracking any adverse events or serious adverse events related to rituximab.
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy outcome as measured by Time to ≥ 2 points improvement on the CAS.
Time Frame: 1 year
|
Time to ≥ 2 points improvement on the CAS.
|
1 year
|
Efficacy outcome as measured by Decrease in exophthalmos (measured in mm using the same Hertel exophthalmometer and same intercanthal distance for an individual patient).
Time Frame: 1 year
|
Decrease in exophthalmos (measured in mm using the same Hertel exophthalmometer and same intercanthal distance for an individual patient).
|
1 year
|
Efficacy outcome
Time Frame: 1 year
|
Decrease in lid aperture (distance between the lid margins in mm with patient looking in the primary position, sitting relaxed and with distant fixation).
|
1 year
|
Efficacy outcome as measured by Subjective diplopia score
Time Frame: 1 year
|
Subjective diplopia score (0=no diplopia; 1=intermittent, i.e. diplopia in primary position of gaze, when tired or when first awakening; 2= inconstant, i.e. diplopia at extremes of gaze; 3=constant, i.e. continuous diplopia in primary or reading position).
|
1 year
|
Efficacy outcome as measured by Improvement in quality of life as measured by an SF-36 and GoQoL.
Time Frame: 1 year
|
Improvement in quality of life as measured by an SF-36 and GoQoL.
|
1 year
|
Efficacy outcome as measured by Immunologic markers and mechanistic analyses to include studies of peripheral blood and thyroid B and T cells and autoantibody levels, thyroid volume, cellularity and function.
Time Frame: 1 year
|
Immunologic markers and mechanistic analyses to include studies of peripheral blood and thyroid B and T cells and autoantibody levels, thyroid volume, cellularity and function.
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Niveditha Mohan, MD, University of Pittsburgh Medical Center
Publications and helpful links
General Publications
- Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010 Feb 25;362(8):726-38. doi: 10.1056/NEJMra0905750.
- Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM; European Group on Graves' Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008 Mar;158(3):273-85. doi: 10.1530/EJE-07-0666. No abstract available.
- Yeatts RP. Quality of life in patients with Graves ophthalmopathy. Trans Am Ophthalmol Soc. 2005;103:368-411.
- HALES IB, RUNDLE FF. Ocular changes in Graves' disease. A long-term follow-up study. Q J Med. 1960 Jan;29:113-26. No abstract available.
- Stan MN, Garrity JA, Bahn RS. The evaluation and treatment of graves ophthalmopathy. Med Clin North Am. 2012 Mar;96(2):311-28. doi: 10.1016/j.mcna.2012.01.014. Epub 2012 Feb 22.
- Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol (Oxf). 2003 Mar;58(3):280-7. doi: 10.1046/j.1365-2265.2003.01708.x.
- Douglas RS, Gupta S. The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol. 2011 Sep;22(5):385-90. doi: 10.1097/ICU.0b013e3283499446.
- Tuscano JM, Harris GS, Tedder TF. B lymphocytes contribute to autoimmune disease pathogenesis: current trends and clinical implications. Autoimmun Rev. 2003 Mar;2(2):101-8. doi: 10.1016/s1568-9972(02)00148-9.
- Shen S, Chan A, Sfikakis PP, Hsiu Ling AL, Detorakis ET, Boboridis KG, Mavrikakis I. B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic. Surv Ophthalmol. 2013 May-Jun;58(3):252-65. doi: 10.1016/j.survophthal.2012.10.006. Epub 2012 Dec 17.
- Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol. 2011 Oct;23(5):613-9. doi: 10.1016/j.coi.2011.07.006. Epub 2011 Aug 16.
- Peng D, Xu B, Wang Y, Guo H, Jiang Y. A high frequency of circulating th22 and th17 cells in patients with new onset graves' disease. PLoS One. 2013 Jul 11;8(7):e68446. doi: 10.1371/journal.pone.0068446. Print 2013.
- Kim SE, Yoon JS, Kim KH, Lee SY. Increased serum interleukin-17 in Graves' ophthalmopathy. Graefes Arch Clin Exp Ophthalmol. 2012 Oct;250(10):1521-6. doi: 10.1007/s00417-012-2092-7. Epub 2012 Jul 1.
- Huang D, Xu N, Song Y, Wang P, Yang H. Inflammatory cytokine profiles in the tears of thyroid-associated ophthalmopathy. Graefes Arch Clin Exp Ophthalmol. 2012 Apr;250(4):619-25. doi: 10.1007/s00417-011-1863-x. Epub 2011 Nov 30.
- Ma CS, Deenick EK. Human T follicular helper (Tfh) cells and disease. Immunol Cell Biol. 2014 Jan;92(1):64-71. doi: 10.1038/icb.2013.55. Epub 2013 Oct 22.
- Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G, Foucat E, Dullaers M, Oh S, Sabzghabaei N, Lavecchio EM, Punaro M, Pascual V, Banchereau J, Ueno H. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 2011 Jan 28;34(1):108-21. doi: 10.1016/j.immuni.2010.12.012. Epub 2011 Jan 6. Erratum In: Immunity. 2011 Jan 28;34(1):135.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO14060524
- UL1TR000005 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thyroid Eye Disease
-
Huijing YeCompletedThyroid Related Eye DiseaseChina
-
Neothetics, IncCompletedThyroid-Related Eye DiseaseAustralia, New Zealand
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingThyroid Eye Disease, TEDChina
-
Harbour BioMed (Guangzhou) Co. Ltd.RecruitingThyroid OphthalmopathyChina
-
Horizon Therapeutics USA, Inc.CompletedThyroid Eye Disease | Chronic (Inactive) Thyroid Eye DiseaseUnited States
-
Lassen Therapeutics Inc.RecruitingEye Diseases | Endocrine System Diseases | Thyroid Eye Disease | Graves Ophthalmopathy | Orbital Diseases | Thyroid Associated Ophthalmopathy | Graves Orbitopathy | ProptosisUnited States, United Kingdom, Spain
-
Horizon Pharma USA, Inc.Recruiting
-
Assiut UniversityNot yet recruiting
-
Immunovant Sciences GmbHRecruitingThyroid Eye DiseaseUnited States, Belgium, Latvia, Hungary, Spain, Slovakia, Puerto Rico, New Zealand, Turkey
-
Iran University of Medical SciencesWithdrawnThyroid Eye DiseaseIran, Islamic Republic of